[  ]	REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934; or
[x]	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended November 30, 2013; or
[  ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934; or
[  ]	SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report …………

Title of each class		Name of each exchange on which registered
Common shares, no par value		NASDAQ TSX

U.S. GAAP [x]

International Financial Reporting Standards as issued by    the International Accounting Standards Board [  ]

Other [  ]

 

 

Number		Exhibit		Footnote
1.1		Articles of Incorporation of the Company and Amendments thereto		(4)
1.2		By-laws of the Company		(4)
4.1		IPC Arrangement Agreement		(4)
4.2		The acknowledgement and agreement of the Company dated October 22, 2009 to be bound by the performance based stock option agreement dated September 10, 2004 pursuant to which Drs. Isa and Amina Odidi are entitled to purchase up to 2,763,940 of the Company’s shares upon payment of U.S.$3.62 per share, subject to satisfaction of the performance vesting conditions		(4)
4.3		The amended and restated promissory note dated October 22, 2009 for up to $2,300,000 issued by Intellipharmaceutics Corp. to Isa Odidi and Amina Odidi for advances that may be made by them from time to time to the Company		(4)
4.51		Securities purchase agreement for February 1, 2011 private placement		(3)
4.52		Registration rights agreement for February 1, 2011 private placement		(3)
4.53		Combined Series A/B common share purchase warrant for February 1, 2011 private placement		(3)
4.54		Placement Agent Agreement between Intellipharmaceutics International Inc. and Roth Capital Partners, LLC, dated March 9, 2012		(5)
4.55		Form of Subscription Agreement (incorporated by reference to Exhibit A attached to Exhibit 4.54		(5)
4.56		12% convertible term debenture dated January 10, 2013 in principal amount of $1,500,000		(2)
4.57		Lease as amended between Finley W. McLachlan Ltd. and Intellipharmaceutics Corp. for premises at 30 Worcester Road, Toronto, Ontario, Canada.		(2)
4.58		Placement Agent Agreement between Intellipharmaceutics International Inc. and Roth Capital Partners, LLC, Brean Capital, LLC and Maxim Group, LLC, dated March 19, 2013		(6)
4.59		Form of Subscription Agreement (incorporated by reference to Exhibit A attached to Exhibit 4.58)		(6)
4.60		Form of Warrants (incorporated by reference to Exhibit B attached to Exhibit 4.58)		(6)
4.61		Underwriting Agreement between Intellipharmaceutics International Inc. and Maxim Group, LLC, as representative of the underwriters named in Schedule I thereto, dated July 26, 2013		(7)
4.62		Form of Warrants		(7)
4.63		Equity Distribution Agreement between Intellipharmaceutics International Inc. and Roth Capital Partners, LLC, dated November 27, 2013		(8)
4.64 (†)		License and Commercialization Agreement  dated as of November 21, 2005, between Intellipharmaceutics Corp., and Par Pharmaceutical, Inc., as amended by the First Amendment To License and Commercialization Agreement dated as of August 2011, and as further amended by the Second Amendment to License and Commercialization Agreement dated as of September 24, 2013		(10)
8.1		List of subsidiaries		(1)
11.1		Code of Business Conduct and Ethics		(4)
12.1		Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934		(10)
12.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934		(10)
13.1		Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002		(1)
13.2		Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002		(1)
15.1		Consent of Independent Registered Public Accounting Firm		(1)

101		XBRL (Extensible Business Reporting Language). The following materials from Intellipharmaceutics International Inc.’s Annual Report on Form 20-F for the fiscal year-ended November 30, 2013, formatted in XBRL:		(1)(9)
		(i) Consolidated balance sheets as at November 30, 2013 and 2012 (restated)
		(ii) Consolidated statements of operations and comprehensive loss for the years ended November 30, 2013, 2012 and 2011

		(iii) Consolidated statements of shareholders’ deficiency for the years ended November 30, 2013, 2012 and 2011(restated)
		(iv) Consolidated statements of cash flows for the years ended November 30, 2013, 2012 and 2011
		(v) Notes to the consolidated financial statements

(1)	Previously filed as exhibits to Original Form 20-F.
(2)	Incorporated herein by reference to the Company’s annual report on Form 20-F for the fiscal year ended November 30, 2012 as filed on January 31, 2013.

(3)	Incorporated herein by reference to the Company’s annual report on Form 20-F for the fiscal year ended November 30, 2010 as filed on May 31, 2011.

(4)	Incorporated herein by reference to the Company’s annual report on Form 20-F for the fiscal year ended November 30, 2009 as filed on June 1, 2010.

(5)	Incorporated herein by reference to the Company’s report on Form 6-K for the month of March 2012 as filed on March 9, 2012.

(6)	Incorporated herein by reference to the Company’s report on Form 6-K for the month of March 2013 as filed on March 19, 2013.

(7)	Incorporated herein by reference to the Company’s report on Form 6-K for the month of July 2013 as filed on July 26, 2013 (SEC Accession No. 0001171843-13-002968).

(8)	Incorporated herein by reference to the Company’s report on Form 6-K for the month of November 2013 as filed on November 27, 2013.

(9)	XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
(10)	Filed herewith.